The Healthcare Ministry of Ukraine has updated upper wholesale and retail prices of medicines that are included in the Affordable Medicines reimbursement program. The price updates are outlined in the ministry’s decree #2, which was published on the institution’s website, Interfax-Ukraine reports.
Corporations that are involved in manufacturing or imports of pharmaceuticals must submit their applications for reimbursement until 11 January 2018.
The updated register of pharmaceuticals that are subject to reimbursement now comprises 23 international non-proprietary names, including one added in late December – Losartan for treatment of cardiovascular diseases and Glibeclamide for treatment of diabetes mellitus of second type.
The ministry announced that the amendments will introduce a new pricing mechanism. “After setting the upper prices for pharmaceuticals, companies will have another five days to slash their price offers and thus replenish the list of goods to be reimbursed by state funds,” the Healthcare Ministry explained.
The ministry expects that consumption of such pharmaceuticals will increase by 30% in physical terms, without impacting the program budget. The number of such items is expected to expand by around 10 products.
Reference price of each active substance is determined separately. The upper-limit wholesale prices are based on the median price of the item in five neighboring countries – Poland, Slovakia, Hungary, the Czech Republic and Latvia. The list of medicines that are subject to reimbursement from the state budget is reviewed twice a year – in January and July – to update prices.